Total Payments
$12,956
2024 Payments
$1,419
Companies
45
Transactions
611
Medicare Patients
736
Medicare Billing
$89,535
Payment Breakdown by Category
Food & Beverage$12,707 (98.1%)
Education$124.45 (1.0%)
Other$74.40 (0.6%)
Gifts$49.36 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,707 | 599 | 98.1% |
| Education | $124.45 | 2 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $74.40 | 6 | 0.6% |
| Gift | $49.36 | 4 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SK Life Science, Inc. | $892.99 | 44 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $803.29 | 52 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $771.94 | 23 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $769.32 | 37 | $0 (2024) |
| UCB, Inc. | $665.22 | 34 | $0 (2023) |
| ABBVIE INC. | $605.52 | 31 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $581.67 | 23 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $568.23 | 27 | $0 (2024) |
| Biogen, Inc. | $526.18 | 30 | $0 (2024) |
| EMD Serono, Inc. | $509.71 | 24 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,419 | 54 | ACADIA Pharmaceuticals Inc ($235.67) |
| 2023 | $1,562 | 60 | Otsuka America Pharmaceutical, Inc. ($238.40) |
| 2022 | $1,248 | 75 | ABBVIE INC. ($168.48) |
| 2021 | $2,038 | 103 | SK Life Science, Inc. ($267.37) |
| 2020 | $1,138 | 59 | Novartis Pharmaceuticals Corporation ($205.29) |
| 2019 | $2,382 | 114 | Teva Pharmaceuticals USA, Inc. ($484.84) |
| 2018 | $1,573 | 63 | Amgen Inc. ($333.60) |
| 2017 | $1,596 | 83 | Allergan Inc. ($317.05) |
All Payment Transactions
611 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.93 | General |
| 12/20/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: NEUROLOGY | ||||||
| 12/19/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $121.82 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Neurology | ||||||
| 11/20/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.71 | General |
| 11/02/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: Neurology | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $32.23 | General |
| Category: Neurology | ||||||
| 10/22/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $29.54 | General |
| 10/16/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $5.70 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/09/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $29.71 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.38 | General |
| Category: PSYCHIATRY | ||||||
| 09/25/2024 | Amneal Pharmaceuticals LLC | ONGENTYS 50MG CAPSULES 30 (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: NEUROLOGY | ||||||
| 09/20/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $20.86 | General |
| 09/17/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Neurology | ||||||
| 09/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Rare Disease | ||||||
| 08/29/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $26.65 | General |
| Category: Neurology | ||||||
| 08/28/2024 | Amneal Pharmaceuticals LLC | ONGENTYS 50MG CAPSULES 30 (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: NEUROLOGY | ||||||
| 08/27/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.43 | General |
| 08/13/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $7.37 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/18/2024 | Genentech USA, Inc. | Activase (Biological), Ocrevus | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Metabolism & Primary Care | ||||||
| 07/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $32.30 | General |
| Category: PSYCHIATRY | ||||||
| 07/04/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $18.03 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 109 | 136 | $21,322 | $12,064 |
| 2022 | 4 | 136 | 169 | $29,867 | $16,380 |
| 2021 | 4 | 230 | 280 | $52,111 | $27,847 |
| 2020 | 5 | 261 | 319 | $60,124 | $33,244 |
Total Patients
736
Total Services
904
Medicare Billing
$89,535
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 70 | $6,204 | $3,893 | 62.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 29 | $8,700 | $3,726 | 42.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $4,168 | $3,119 | 74.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 15 | $2,250 | $1,326 | 58.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 56 | 57 | $17,100 | $8,551 | 50.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 76 | $6,736 | $4,260 | 63.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $3,031 | $1,994 | 65.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 20 | $3,000 | $1,575 | 52.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 98 | 99 | $29,700 | $14,773 | 49.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 92 | $8,154 | $5,129 | 62.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 54 | 66 | $9,900 | $5,120 | 51.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $4,357 | $2,825 | 64.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 121 | 122 | $36,600 | $18,862 | 51.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 64 | 86 | $12,900 | $6,972 | 54.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 44 | 79 | $7,002 | $4,690 | 67.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 13 | 13 | $2,463 | $1,852 | 75.2% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Facility | 2020 | 19 | 19 | $1,159 | $868.60 | 74.9% |
About Dr. .Jeffrey Gaitz, M.D
Dr. .Jeffrey Gaitz, M.D is a Neurology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922044510.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. .Jeffrey Gaitz, M.D has received a total of $12,956 in payments from pharmaceutical and medical device companies, with $1,419 received in 2024. These payments were reported across 611 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($12,707).
As a Medicare-enrolled provider, Gaitz has provided services to 736 Medicare beneficiaries, totaling 904 services with total Medicare billing of $89,535. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Houston, TX
- Active Since 06/21/2006
- Last Updated 07/25/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1922044510
Products in Payments
- NUPLAZID (Drug) $769.32
- APTIOM (Drug) $530.27
- REXULTI (Drug) $463.16
- RYTARY (Drug) $453.00
- UBRELVY (Drug) $439.35
- GOCOVRI (Drug) $427.21
- Briviact (Drug) $377.43
- AJOVY (Drug) $374.34
- KESIMPTA (Drug) $364.51
- TECFIDERA (Drug) $308.11
- INGREZZA (Drug) $302.52
- TROKENDI XR (Drug) $293.57
- Leqembi (Drug) $289.02
- Vimpat (Drug) $270.25
- EMGALITY (Drug) $268.81
- AIMOVIG (Biological) $263.33
- Aimovig (Biological) $262.47
- Rebif (Biological) $259.74
- SOLIRIS (Drug) $249.49
- Soliris (Drug) $240.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Houston
William Ondo, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Annette Howard, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M
Paul Schulz, M.d, M.D
Neurology — Payments: $943,067
Neurology $943,067
Amit Verma, Md, MD
Neurology — Payments: $817,815
Neurology $817,815
Dr. Randolph Evans, Md, MD
Neurology — Payments: $715,948
Neurology $715,948
Dr. John Volpi, Md, MD
Neurology — Payments: $569,676
Neurology $569,676